Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KD-295
- Development stage
- Phase 3
- Lead developer
- KM Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
KD-295 is an inactivated Zika virus vaccine candidate developed by KM Biologics (formerly The Chemo-Sero-Therapeutic Research Institute, also known as Kaketsuken). The vaccine is produced using cell culture-based technology and is designed to prevent Zika virus infection by eliciting a protective immune response. It is administered via intramuscular injection. A Phase 1 clinical trial (jRCT2080221412) was conducted in Japan to evaluate the safety, tolerability, and immunogenicity of the vaccine in healthy adult males, utilizing a two-dose regimen administered 21 days apart at two different dose levels.
- Other names
- Zika virus vaccine
02
Targets
B-cell receptor specific for Zika virus envelope and pre-membrane proteins (ZIKV E/prM-specific BCR)TCR-ZIKV (Zika virus-specific T-cell receptor)ZIKV E (Zika virus envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on KD-295.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD-295.